GILD241227C104000
- 0.00
- 0.000.00%
Gilead Sciences Newsroom
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Jim Cramer on Gilead Sciences, Inc. (GILD): 'I Don't Think The Business Is Worth As Much As The Stock Is Selling'
Gilead Sciences, Inc. (GILD) Is Attracting Investor Attention: Here Is What You Should Know
Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results
Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
Gilead Sciences Invests $20.1 Million in Assembly Biosciences
Gilead Sciences (GILD) Made Big Announcements in Q3
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Gilead Sciences to Present at Upcoming Investor Conference
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
19% Of This Gilead Sciences Insider's Holdings Were Sold
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
(GILD) - Analyzing Gilead Sciences's Short Interest
Gilead Raises Assembly Bio Stake to ~30%
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding